Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least the two following signs, in at least one eye\* (the same eye should fulfill both criteria):~  * Presence of giant papillae with a diameter ≥ 1 mm on the upper tarsal conjunctiva AND~ * Superficial keratitis~* At least two of the following ocular symptoms with a score \> 2 in at least one eye\*: burning/stinging, tearing, itching, pain, sticky eyelids, foreign body sensation, mucus discharge, and photophobia.~* Hyperemia score equal to or greater than 2.~Exclusion Criteria:~* Concomitant corneal ulcer of infectious origin.~* Active ocular herpes~* Disease that could possibly interfere with the interpretation of the study results: active uveitis (defined by Tyndall score \> 0), previous history of ocular hypertension or glaucoma, or condition incompatible with the frequent assessments needed by the study.~* Active herpes.~* History of malignancy or a recurrence in the last 5 years.~* Abnormality of nasolacrimal drainage apparatus.~* Concomitant disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, trouble with thyroid secretions, etc.) or judged by the investigator to be incompatible with the study (e.g. current systemic infections), or condition incompatible with the frequent assessments needed by the study.~* Known hypersensitivity to one of the components of the investigational medicinal products (IMP) or test products.~* Severe systemic allergy requiring systemic treatment at study entry.~* Female of childbearing potential.~* History of drug or alcohol addiction (\> 50g/day, 5 glasses alcohol/day).

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NOVA22007 0.05% (Type: EXPERIMENTAL): four times daily
- NOVA22007 0.1% (Type: EXPERIMENTAL): four times daily
- Vehicle (Type: SHAM_COMPARATOR): administered four times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).